Carillon Tower Advisers Inc. Lowers Holdings in Bruker Co. (BRKR)

Carillon Tower Advisers Inc. lessened its stake in Bruker Co. (NASDAQ:BRKR) by 2.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 170,742 shares of the medical research company’s stock after selling 4,525 shares during the quarter. Carillon Tower Advisers Inc.’s holdings in Bruker were worth $6,563,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Hanseatic Management Services Inc. boosted its stake in Bruker by 52.0% during the 4th quarter. Hanseatic Management Services Inc. now owns 1,692 shares of the medical research company’s stock worth $50,000 after acquiring an additional 579 shares during the last quarter. Captrust Financial Advisors lifted its stake in Bruker by 164.7% in the fourth quarter. Captrust Financial Advisors now owns 1,824 shares of the medical research company’s stock valued at $54,000 after buying an additional 1,135 shares in the last quarter. SG Americas Securities LLC bought a new position in Bruker in the fourth quarter valued at approximately $176,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in Bruker in the fourth quarter valued at approximately $192,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Bruker by 8.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,136 shares of the medical research company’s stock valued at $212,000 after buying an additional 550 shares in the last quarter. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Shares of BRKR stock opened at $41.72 on Thursday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.27 and a current ratio of 2.12. The firm has a market capitalization of $6.53 billion, a PE ratio of 29.80, a price-to-earnings-growth ratio of 2.21 and a beta of 1.44. Bruker Co. has a 12 month low of $26.10 and a 12 month high of $44.47.



Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.28 EPS for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.04. The business had revenue of $461.40 million for the quarter, compared to analyst estimates of $450.46 million. Bruker had a net margin of 9.53% and a return on equity of 26.28%. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.24 earnings per share. Analysts anticipate that Bruker Co. will post 1.61 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 21st. Stockholders of record on Monday, June 3rd will be given a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.38%. The ex-dividend date of this dividend is Friday, May 31st. Bruker’s dividend payout ratio is presently 11.43%.

A number of research analysts have weighed in on BRKR shares. Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $46.00 price target (up previously from $39.00) on shares of Bruker in a research note on Monday, May 6th. BTIG Research reissued a “buy” rating and issued a $44.00 price objective (up previously from $42.00) on shares of Bruker in a research report on Tuesday, February 12th. Zacks Investment Research raised shares of Bruker from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research report on Tuesday, January 29th. Deutsche Bank raised shares of Bruker from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $40.00 to $50.00 in a research report on Friday, April 12th. Finally, BidaskClub lowered shares of Bruker from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 4th. One analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $43.71.

TRADEMARK VIOLATION WARNING: “Carillon Tower Advisers Inc. Lowers Holdings in Bruker Co. (BRKR)” was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://dakotafinancialnews.com/2019/05/16/carillon-tower-advisers-inc-lowers-holdings-in-bruker-co-brkr.html.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Featured Article: What is a Call Option?

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.